Commonwealth Bank of Australia lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,814 shares of the pharmaceutical company’s stock after selling 718 shares during the quarter. Commonwealth Bank of Australia’s holdings in Vertex Pharmaceuticals were worth $425,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Achmea Investment Management B.V. grew its position in Vertex Pharmaceuticals by 68.0% in the second quarter. Achmea Investment Management B.V. now owns 8,668 shares of the pharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 3,507 shares in the last quarter. NorthCoast Asset Management LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $782,000. Delta Lloyd Asset Management N.V. acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $3,285,000. Prudential Financial Inc. grew its position in Vertex Pharmaceuticals by 12.8% in the second quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock valued at $57,312,000 after acquiring an additional 50,350 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in Vertex Pharmaceuticals by 89.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 14,463 shares of the pharmaceutical company’s stock valued at $1,863,000 after acquiring an additional 6,836 shares in the last quarter. 93.33% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP Michael Parini sold 2,125 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $152.93, for a total transaction of $324,976.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $151.64, for a total value of $521,186.68. The disclosure for this sale can be found here. Insiders have sold 218,519 shares of company stock worth $31,819,910 over the last 90 days. 1.80% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $137.28 on Thursday. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The stock has a market capitalization of $34,991.63, a price-to-earnings ratio of 230.60, a P/E/G ratio of 3.31 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. During the same period last year, the business posted $0.16 earnings per share. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

Several research firms have recently commented on VRTX. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. Needham & Company LLC reiterated a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. DA Davidson began coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $200.00 target price for the company. Finally, BTIG Research began coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $200.00 target price for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have issued a buy rating to the company. Vertex Pharmaceuticals presently has an average rating of “Buy” and an average target price of $173.15.

ILLEGAL ACTIVITY NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Sold by Commonwealth Bank of Australia” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/07/vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-commonwealth-bank-of-australia.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.